The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials

References

• de Jager DJ, Grootendorst DC, Jager KJ, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009;302:1782–1789
   PubMed Web of Science ®Google Scholar
• Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853–906
   PubMed Web of Science ®Google Scholar
• Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014–1021
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252
   PubMed Web of Science ®Google Scholar
• Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179–1187
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607–617
   PubMed Web of Science ®Google Scholar
• Ketteler M, Biggar PH. Use of phosphate binders in chronic kidney disease. Curr Opin Nephrol Hypertens. 2013;22:413–420
   PubMed Web of Science ®Google Scholar
• Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in hemodialysis patients. Nephrol Dial Transplant. 2004;19:1489–1496
   PubMed Web of Science ®Google Scholar
• Kakuta T, Tanaka R, Hyodo T, et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis. 2011;57:422–431
   PubMed Web of Science ®Google Scholar
• Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008;51:952–965
   PubMed Web of Science ®Google Scholar
• Shigematsu T. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol. 2008;70:404–410
   PubMed Web of Science ®Google Scholar
• Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896–1900
   PubMed Web of Science ®Google Scholar
• Bradburn M, Deeks J, Altman D. Sbe24: Metan – an alternative meta-analysis command. Stata Technical Bull Reprints. 1998;8: 86–100
   Google Scholar
• Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889–894
   PubMed Web of Science ®Google Scholar
• Lee YK, Choi HY, Shin SK, Lee HY. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: A randomized prospective study. Clin Nephrol. 2013;79:136–142
   Google Scholar
• Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Donate-Correa J, Cazana-Perez V, Garcia-Perez J. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:2272–2279
   PubMed Web of Science ®Google Scholar
• Sadek T, Mazouz H, Bahloul H, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: An open-label, randomized study. Nephrol Dial Transplant. 2003;18:582–588
   PubMed Web of Science ®Google Scholar
• Barreto DV, Barreto Fde C, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification – results from the BRiC study. Nephron Clin Pract. 2008;110:c273–c283
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Selgas R, Caputo F, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant. 2009;24:278–285
   PubMed Web of Science ®Google Scholar
• Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824
   PubMed Web of Science ®Google Scholar
• Braun J, Asmus HG, Holzer H, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification. Clin Nephrol. 2004;62:104–115
   PubMed Web of Science ®Google Scholar
• Kalil RS, Flanigan M, Stanford W, Haynes WG. Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: A prospective pilot study. Clin Nephrol. 2012;78:1–9
   PubMed Web of Science ®Google Scholar
• Ferreira A, Frazao JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008,19:405–412
   PubMed Web of Science ®Google Scholar
• Freemont AJ, Hoyland JA, Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol. 2005;64:428–437
   PubMed Web of Science ®Google Scholar
• Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant. 2006;21:2217–2224
   PubMed Web of Science ®Google Scholar
• Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in hemodialysis: A pilot randomized controlled trial. Nephrology (Carlton). 2011;16:290–298
   PubMed Web of Science ®Google Scholar
• Wesseling-Perry K, Harkins GC, Wang HJ, et al. Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatr Nephrol. 2009;24:1355–1361
   Google Scholar
• Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130–1137
   PubMed Web of Science ®Google Scholar
• Takei T, Otsubo S, Uchida K, et al. Effects of sevelamer on the progression of vascular calcification in patients on chronic hemodialysis. Nephron Clin Pract. 2008;108:c278–c283
   PubMedGoogle Scholar
• Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. 2004;65:1914–1926
   PubMed Web of Science ®Google Scholar
• Torres PA, De Broe M. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney Int. 2012;82:19–25
   PubMed Web of Science ®Google Scholar
• London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15:1943–1951
   PubMed Web of Science ®Google Scholar
• Andia CJB. Adynamic bone and chronic renal failure: An overview. Am J Med Sci. 2000;320:81–84
   Google Scholar
• Zhang Q, Li M, Lu Y, et al. Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract. 2010;115:c259–c267
   Google Scholar
• Jamal SA, Fitchett D, Lok CE, Mendelssohn DC, Tsuyuki RT. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: A meta-analysis. Nephrol Dial Transplant. 2009;24:3168–3174
   PubMed Web of Science ®Google Scholar
• Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: A randomized clinical trial. Arthritis Rheum. 2005;52:290–295
   PubMed Web of Science ®Google Scholar
• von Rosenberg SJ, Wehr UA. Lanthanum salts improve bone formation in a small animal model of post-menopausal osteoporosis. J Anim Physiol Anim Nutr (Berl). 2012;96:885–894
   Google Scholar
• Sampath TK, Simic P, Moreno S, et al. Sevelamer restores bone volume and improves bone microarchitecture and strength in aged ovariectomized rats. Endocrinology. 2008;149:6092–6102
   PubMedGoogle Scholar
• Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: Synthesis of best evidence for clinical decisions. Ann Intern Med. 1997;126:376–380
   PubMed Web of Science ®Google Scholar